Results of a Nation-Wide Survey Evaluating Psychotropic Medication Use in Fragile X Syndrome

被引:18
作者
Valdovinos, Maria G. [1 ]
Parsa, Rahul A. [2 ]
Alexander, Michelle L. [1 ]
机构
[1] Drake Univ, Dept Psychol, Des Moines, IA 50312 USA
[2] Drake Univ, Actuarial Sci Program, Des Moines, IA 50312 USA
关键词
Fragile X syndrome; Psychotropic medication; Side effects; DEVELOPMENTAL-DISABILITIES; MENTAL-RETARDATION; PHENOTYPES;
D O I
10.1007/s10882-008-9123-7
中图分类号
G76 [特殊教育];
学科分类号
040109 ;
摘要
Fragile X syndrome (FXS) is the most common inherited cause of mental retardation. The behavioral phenotype associated with FXS includes hyperactivity, anxiety, and sometimes problem behaviors for which stimulants, antipsychotics, and SSRI antidepressants are prescribed. Little information, however, is known about the side effects individuals with FXS may experience as a result of taking these medications. Using a nation-wide survey, this study examined the prescription patterns of psychotropic medication use within the FXS population and the prevalence of side effects associated with psychotropic medication use by people diagnosed with FXS. Significant associations were found between the most commonly prescribed medications and side effects for our total sample. These findings give insight to the different dimensions of medication use in people diagnosed with FXS.
引用
收藏
页码:23 / 37
页数:15
相关论文
共 19 条
  • [1] The mGIuR theory of fragile X mental retardation
    Bear, MF
    Huber, KM
    Warren, ST
    [J]. TRENDS IN NEUROSCIENCES, 2004, 27 (07) : 370 - 377
  • [2] Correlates across the structural, functional, and molecular phenotypes of fragile X syndrome
    Beckel-Mitchener, A
    Greenough, WT
    [J]. MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS, 2004, 10 (01): : 53 - 59
  • [3] Psychopharmacology in fragile X syndrome - Present and future
    Berry-Kravis, E
    Potanos, K
    [J]. MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS, 2004, 10 (01): : 42 - 48
  • [4] Berry-Kravis E, 2002, DEV MED CHILD NEUROL, V44, P724
  • [5] CYCLIC-AMP METABOLISM IN FRAGILE-X SYNDROME
    BERRYKRAVIS, E
    HUTTENLOCHER, PR
    [J]. ANNALS OF NEUROLOGY, 1992, 31 (01) : 22 - 26
  • [6] Understanding the biological underpinnings of fragile X syndrome
    Chiurazzi, P
    Neri, G
    Oostra, BA
    [J]. CURRENT OPINION IN PEDIATRICS, 2003, 15 (06) : 559 - 566
  • [7] Hagerman R., 2002, FRAGILE X SYNDROME, P3
  • [8] Hagerman RJ, 1997, WESTERN J MED, V166, P129
  • [9] HAGERMAN RJ, 1994, DEV BRAIN DYSFUNCT, V7, P155
  • [10] A CONTROLLED TRIAL OF STIMULANT MEDICATION IN CHILDREN WITH THE FRAGILE-X SYNDROME
    HAGERMAN, RJ
    MURPHY, MA
    WITTENBERGER, MD
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS, 1988, 30 (1-2): : 377 - 392